Your browser doesn't support javascript.
loading
Does lactate clearance prognosticates outcomes in ECMO therapy: a retrospective observational study.
Mungan, Ibrahim; Kazanci, Dilek; Bektas, Serife; Ademoglu, Derya; Turan, Sema.
Afiliação
  • Mungan I; Department of Intensive Care Unit, Turkey Advanced Speciality Education and Research Hospital, Altindag, Ankara, Turkey. imungan@gmail.com.
  • Kazanci D; Department of Intensive Care Unit, Turkey Advanced Speciality Education and Research Hospital, Altindag, Ankara, Turkey.
  • Bektas S; Department of Intensive Care Unit, Turkey Advanced Speciality Education and Research Hospital, Altindag, Ankara, Turkey.
  • Ademoglu D; Department of Intensive Care Unit, Turkey Advanced Speciality Education and Research Hospital, Altindag, Ankara, Turkey.
  • Turan S; Department of Intensive Care Unit, Turkey Advanced Speciality Education and Research Hospital, Altindag, Ankara, Turkey.
BMC Anesthesiol ; 18(1): 152, 2018 10 24.
Article em En | MEDLINE | ID: mdl-30355289
ABSTRACT

BACKGROUND:

ECMO support is a final treatment modality for patients in the refractory cardiogenic arrest and postcardiotomy cardiogenic shock with an utmost importance. Eventhough it is linked to high mortality, its usage gains popularity worldwide. We assessed the fluctuation of lactate levels and the clearance of lactate during the ECMO therapy and its prognostic role on mortality.

METHODS:

Data were gathered on all patients receiving ECMO therapy longer than 48 h between January 2015 and December 2017 retrospectively. Blood lactate had been recorded before ECMO implantation and at specific time points during ECMO support as a routine procedure. In this study, the Lactate clearance at specific time points (Lactate clearance-1) and the duration that lactate cleared more than 10% of the initial lactate level (Lactate clearance-2) was measured. Statistical analysis included Mann Whitney U-test and ROC-curves to predict 30-day mortality.

RESULTS:

Fourty-eight patients underwent ECMO therapy for refractory cardiogenic shock resulting in 70.8% mortality. The lactate levels before and after ECMO therapy as well as the dynamic changes were significantly correlated with mortality variable. With AUC calculation, LC-2 has a strong discrimination (AUC = 0.97) on 30-day survivors and nonsurvivors. LAE-LBE (AUC = 0.785), L48-LBE (AUC = 0.706) showed moderate predictive power on 30-day mortality.

CONCLUSIONS:

Changes in lactate levels after ECMO implantation is an important tool to assess effective circulatory support and it is found superior to single lactate measurements as a prognostic sign of mortality in our study. Based on our results, an early insertion of ECMO before lactate gets high was suggested. Serial changes on lactate levels and calculation of its clearance may be superior to single lactate on both effective circulatory support and as prognostic prediction. LC-2 showed a strong discrimination on 30-day mortality.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Oxigenação por Membrana Extracorpórea / Ácido Láctico Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Oxigenação por Membrana Extracorpórea / Ácido Láctico Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article